Acta Scientific Ophthalmology (ISSN: 2582-3191)

Editorial Volume 5 Issue 2

Bisphosphonates and Ocular Inflammation

Ali Nouraeinejad1,2*

1Ph.D. in Clinical Ophthalmology, Tehran University of Medical Sciences, Tehran, Iran
2University College London (UCL), London, United Kingdom

*Corresponding Author: Ali Nouraeinejad, Ph.D. in Clinical Ophthalmology, Tehran University of Medical Sciences, Tehran, Iran.

Received: November 24, 2021; Published: January 01, 2022

Abstract

Osteoporosis, as a musculoskeletal disease, is assigned by low bone mass and degradation of bone microarchitecture, culminating in an escalation in bone weakness and propensity to fracture [1,2]. When the cumulative effect of bone resorption is in excess of bone formation, osteoporosis is induced [1]. Osteoporotic fractures are linked to substantial morbidity, mortality, and high healthcare expenses [1].

References

  1. Lewiecki EM. “Bisphosphonates for the treatment of osteoporosis: insights for clinicians”. Therapeutic Advances in Chronic Disease 3 (2010): 115-128.
  2. Garriga C., et al. “Oral bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study”. Annals of the New York Academy of Sciences 1 (2018): 34-46.
  3. Cawthon PM. “Gender differences in osteoporosis and fractures”. Clinical Orthopaedics and Related Research 2011 469(7):1900-1905.
  4. Alswat KA. “Gender Disparities in Osteoporosis”. Journal of Clinical Medicine Research 5 (2017): 382-387.
  5. Kennel KA and Drake MT. “Adverse effects of bisphosphonates: implications for osteoporosis management”. Mayo Clinic Proceedings 7 (2009): 632-638.
  6. Nouraeinejad A. “Handbook of ocular drugs, and ocular side effects of systemic drugs”. Tehran: Tabib Publication (2000).
  7. Nouraeinejad A. “Differential Diagnosis in Optometry and Ophthalmology”. Second Edition. Iran: Noruzi Publication (2017).
  8. Etminan M., et al. “Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study”. Canadian Medical Association Journal 184 (2012): E431-E434.
  9. Rahimy E and Law SK. “Orbital inflammation after zoledronate infusion: an emerging complication”. Canadian Journal of Ophthalmology 48 (2013): e11-e12.
  10. Pazianas M., et al. “Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database”. Journal of Bone and Mineral Research 28 (2013): 455-463.
  11. Pirbhai A., et al. “Bisphosphonate-induced orbital inflammation: a case series and review”. Orbit 34 (2015): 331-335.
  12. Clark EM and Durup D. “Inflammatory eye reactions with bisphosphonates and other osteoporosis medications: what are the risks?”. Therapeutic Advances in Musculoskeletal Disease 1 (2015): 11-16.
  13. Martin Guillén S., et al. “Uveitis Due to Bisphosphonates: A Rare Side Effect?”. Reumatología Clínica 12 (2016): 119.
  14. Mammo Z., et al. “Oral Bisphosphonates and Risk of Wet Age-Related Macular Degeneration”. American Journal of Ophthalmology 168 (2016): 62-67.
  15. Godkhindi Vishwapriya M and Basade Maheboob M. “Zoledronic Acid Induced Orbital Cellulitis-Case Report and Literature Review”. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)4 (2016): 75-79.
  16. Umunakwe OC., et al. “Diffuse ocular and orbital inflammation after zoledronate infusion—case report and review of the literature”. Digital Journal of Ophthalmology 23 (2017): 109-112.
  17. Gomez Escobar LG and Devia DG. “Possible ocular adverse effects attributed to bisphoshonate therapy: Two care reports”. Revista Colombiana de Reumatología 24 (2017): 54-59.
  18. Fraunfelder FW and Fraunfelder FT. “Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects”. Ophthalmology 111 (2004): 1275-1279.
  19. Peterson JD and Bedrossian EH. “Bisphosphonate-associated orbital inflammation—a case report and review”. Orbit 31 (2012): 119-123.
  20. Hewitt RE., et al. “The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins”. Clinical and Experimental Immunology 1 (2005): 101-111.
  21. Kassi G., et al. “Cytokines and insulin resistance after zoledronic acid-induced acute phase response”. Immunological Investigations 6 (2014): 544-555.
  22. French D and Margo C. “Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort”. Retina 28 (2008): 889-893.
  23. Patel DV., et al. “The incidence of acute anterior uveitis after intravenous zoledronate”. Ophthalmology4 (2013): 773-776.
  24. Jones DG., et al. “Synovitis induced by alendronic acid can present as acute carpal tunnel syndrome”. BMJ7482 (2005): 74.

Citation

Citation: Ali Nouraeinejad. “Bisphosphonates and Ocular Inflammation". Acta Scientific Ophthalmology 5.2 (2022): 01-03.

Copyright

Copyright: © 2022 Ali Nouraeinejad. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days
ISI- IF1.042
JCR- IF0.24

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is October 10, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US